TRT monitoring: is total testosterone really not enough?

What's this video probably claiming?

Based on the caption, this creator is arguing that men on testosterone replacement therapy are being under-monitored, specifically that clinicians are checking total testosterone and stopping there. The implied claim is that a broader panel, likely including free testosterone, estradiol, sex hormone-binding globulin (SHBG), luteinizing hormone (LH), follicle-stimulating hormone (FSH), hematocrit, and possibly DHT or prolactin, is what actually explains symptom variability. The framing targets the gap between feeling good on paper versus feeling good in practice. That's a legitimate clinical frustration, and it's one that real endocrinologists and urologists argue about too. The biohacking hashtag does raise a flag though: there's a difference between evidence-based expanded monitoring and the "optimisation" rabbit hole where every number becomes a dial to turn. We don't have the transcript yet, so we're working from what the caption signals.

What does the science actually show?

The short answer is: total testosterone alone is genuinely insufficient, but the science on which additional markers matter most is messier than TikTok usually admits. Free testosterone, calculated or directly measured, correlates more closely with androgen-dependent outcomes in men with abnormal SHBG, according to Vermeulen et al. (1999, Journal of Clinical Endocrinology and Metabolism), whose calculated free testosterone formula is still widely used. SHBG levels vary significantly, especially in men with obesity or metabolic syndrome, so two men with identical total testosterone of say 550 ng/dL can have very different free testosterone. Estradiol matters for libido and bone density, with Finkelstein et al. (2013, NEJM) demonstrating that sexual function in men is regulated by both testosterone and estrogen, not testosterone alone. Hematocrit monitoring is non-negotiable on TRT given erythrocytosis risk, with Bachman et al. (2010, Journal of Clinical Endocrinology and Metabolism) showing hematocrit rises in roughly 30 to 44 percent of men on injectable testosterone depending on dose and formulation.

Where does the social media noise diverge from clinical reality?

The clinical guidelines are actually reasonably aligned with this creator's broad point. The Endocrine Society's 2018 clinical practice guideline recommends monitoring total testosterone, hematocrit, and PSA at minimum, with free testosterone in specific clinical contexts. The American Urological Association similarly recommends follow-up labs at three and six months. Where the social media version diverges is in the implied causality: creators often suggest that optimising estradiol to a specific range, or keeping SHBG at a particular level, will directly produce better libido or mood. The evidence for chasing specific estradiol targets is weak. Some TRT communities obsess over estradiol suppression with aromatase inhibitors, but Helo et al. (2015, Journal of Sexual Medicine) found no clear threshold estradiol level that consistently improved sexual function across patients. Symptom correlation with any single hormone number remains poor. The biohacking framing also tends to push toward more testing than clinical benefit justifies.

What should you actually know?

If you're on TRT and your only follow-up lab is total testosterone, that's a reasonable concern worth raising with your prescriber. At minimum, hematocrit, PSA, and a lipid panel are standard of care. Free testosterone and SHBG become relevant if your total testosterone looks fine but symptoms persist, or if you have obesity, liver disease, or thyroid dysfunction that affects SHBG. Estradiol testing makes sense if you're symptomatic, particularly for low libido or joint pain, but the answer is rarely an aromatase inhibitor unless estradiol is clearly and significantly elevated. LH and FSH are useful for baseline and for understanding whether the axis is suppressed, but on established TRT they change predictably and don't need frequent repeating. The bigger clinical reality is that symptoms drive decisions more than numbers do, which is something the Testosterone Trials (Snyder et al., 2016, NEJM) reinforced: responders and non-responders existed across similar testosterone levels. A good panel informs clinical judgment. It doesn't replace it.